Scholar Rock Holding Corporation - Common Stock (NQ:SRRK)

42.19 -0.01 (-0.02%)

Delayed Quote Updated: 4:00 PM EDT, Oct 9, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Scholar Rock Holding Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

12 13 Next >

Scholar Rock Resubmits Apitegromab Marketing Authorisation Application (MAA) to European Medicines Agency (EMA) for Treatment of Children and Adults with Spinal Muscular Atrophy (SMA)

October 08, 2026

From Scholar Rock

Via Business Wire

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 21, 2026

From Scholar Rock

Via Business Wire

Scholar Rock Announces FDA Approval of ISEMBYLD™ (apitegromab-mstn), the First and Only Muscle-Targeted Treatment for Children and Adults with Spinal Muscular Atrophy (SMA)

September 11, 2026

From Scholar Rock

Via Business Wire

Scholar Rock Receives FDA Fast Track Designation for Apitegromab Facioscapulohumeral Muscular Dystrophy (FSHD) Program as Participant Dosing Commences in Phase 2 FORGE Trial

September 02, 2026

From Scholar Rock

Via Business Wire

Scholar Rock (NASDAQ:SRRK) Rallies 17% as Regulatory Catalysts Outweigh In-Line Q2 Results ↗

August 06, 2026

Via Chartmill

Scholar Rock to Present at Upcoming Investor Conferences

August 27, 2026

From Scholar Rock

Via Business Wire

Scholar Rock Provides Update on Global Apitegromab Regulatory Progress Across U.S., Europe, and Japan

August 21, 2026

From Scholar Rock

Via Business Wire

Scholar Rock Eyes Sept. 30 FDA Decision for SMA Drug Apitegromab ↗

August 17, 2026

Scholar Rock (NASDAQ:SRRK) CEO David Hallal said the company is preparing for a September 30 FDA decision date for apitegromab, its investigational treatment for spinal muscular atrophy, or SMA,...

Via MarketBeat

Scholar Rock (SRRK) Q1 Loss Narrows In Line Awaits PDUFA Decision ↗

May 07, 2026

Via Chartmill

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 14, 2026

From Scholar Rock, Inc.

Via Business Wire

Scholar Rock (SRRK) Q2 2026 Earnings Call Transcript ↗

August 13, 2026

Apitegromab awaits FDA decision on Sept. 30 for spinal muscular atrophy treatment.

Via The Motley Fool

Topics Earnings Economy

Scholar Rock Announces FDA Review of Apitegromab Biologics License Application (BLA) for Spinal Muscular Atrophy (SMA) to Progress with Second Fill-Finish Facility; Approval Decision Anticipated by September 30, 2026 Action Date

August 07, 2026

From Scholar Rock

Via Business Wire

Scholar Rock Q2 Earnings Call Highlights ↗

August 07, 2026

Scholar Rock (NASDAQ:SRRK) said its resubmitted biologics license application for apitegromab remains on track for a U.S. Food and Drug Administration decision by its Sept. 30 PDUFA date, as the...

Via MarketBeat

Topics Earnings

Scholar Rock Reports Second Quarter 2026 Financial Results and Recent Business Highlights

August 06, 2026

From Scholar Rock

Via Business Wire

Scholar Rock to Present at the Canaccord Genuity 46th Annual Growth Conference

July 29, 2026

From Scholar Rock

Via Business Wire

Scholar Rock Provides Update on Timing of Committee for Medicinal Products for Human Use (CHMP) Opinion for Apitegromab Marketing Authorisation Application (MAA) for Spinal Muscular Atrophy (SMA)

July 20, 2026

From Scholar Rock

Via Business Wire

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 17, 2026

From Scholar Rock

Via Business Wire

Scholar Rock to Report Second Quarter 2026 Financial Results on August 6, 2026

July 16, 2026

From Scholar Rock

Via Business Wire

Scholar Rock to Showcase Neuromuscular Research Portfolio at 2026 Annual Cure SMA Research and Clinical Care Meeting and 2026 International Research Congress on FSHD

June 22, 2026

From Scholar Rock

Via Business Wire

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 12, 2026

From Scholar Rock

Via Business Wire

Scholar Rock to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

May 26, 2026

From Scholar Rock

Via Business Wire

Scholar Rock to Present at the 2026 Jefferies Global Healthcare Conference

May 20, 2026

From Scholar Rock, Inc.

Via Business Wire

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 15, 2026

From Scholar Rock, Inc.

Via Business Wire

What to Know About This Fund’s $50 Million Exit From Ascendis Pharma ↗

May 14, 2026

Ascendis Pharma develops long-acting therapies for rare endocrine and pediatric diseases using its proprietary TransCon technology.

Via The Motley Fool

Topics Regulatory Compliance

This Fund Has a $75 Million Bet on a Hair Loss Biotech Stock Up More Than 500% Post-IPO ↗

May 14, 2026

Veradermics develops novel dermatology treatments, targeting both adult and pediatric markets with a research-driven approach.

Via The Motley Fool

Topics Initial Public Offering

Why This Hedge Fund Added $29 Million to a Cancer Stock Already Up 700% ↗

May 14, 2026

This clinical-stage biotech develops targeted therapies for RAS/MAPK pathway-driven cancers, addressing hard-to-treat tumor types.

Via The Motley Fool

Topics Regulatory Compliance

Scholar Rock Q1 Earnings Call Highlights ↗

May 08, 2026

Scholar Rock (NASDAQ:SRRK) said the U.S. Food and Drug Administration has accepted for review its resubmitted Biologics License Application for apitegromab, the company’s investigational treatment for...

Via MarketBeat

Topics Earnings

Scholar Rock (SRRK) Q1 2026 Earnings Transcript ↗

May 08, 2026

Scholar Rock (SRRK) Q1 2026 Earnings Transcript

Via The Motley Fool

Scholar Rock Reports First Quarter 2026 Financial Results and Recent Business Highlights

May 07, 2026

From Scholar Rock

Via Business Wire

Scholar Rock to Present at the BofA Securities 2026 Health Care Conference

April 29, 2026

From Scholar Rock

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9

...

12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.